Search results
Myriad Genetics' (MYGN) New Platform to Advance Cancer Care
Zacks via Yahoo Finance· 5 months agoMyriad Genetics, Inc. MYGN recently launched the Myriad Collaborative Research Registry (“MCRR”) — a...
Here's Why You Should Retain Myriad Genetics (MYGN) Stock Now
Zacks via Yahoo Finance· 2 years agoMyriad Genetics, Inc. MYGN is well-poised for growth, backed by robust testing volumes and a huge...
Myriad Genetics (MYGN) Adds New Test to Oncology Portfolio
Zacks via Yahoo Finance· 12 months agoMyriad Genetics MYGN recently announced the addition of Folate Receptor Alpha (FRα) to its Precise...
Reasons to Hold on to Myriad Genetics (MYGN) Stock for Now
Zacks via Yahoo Finance· 2 years agoMyriad Genetics, Inc. MYGN has been gaining from robust first-quarter 2022 results. Spectacular...
Invitae (NVTA) Q2 2023 Earnings Call Transcript
Motley Fool· 9 months agoHosting the call today is our president and CEO, Ken Knight. In hereditary cancer, guideline expansions and better outcomes are expected to further...
Why Invitae Stock Popped Today
Motley Fool· 7 months agoWhat happened Shares of Invitae (NYSE: NVTA) roared as much as 37% higher early Monday, then settled to trade up 13% as of 3 p.m. ET after the U.S Food...
Myriad Genetics (MYGN) Gets Permit to Expand Tumor Testing
Zacks via Yahoo Finance· 1 year agoMyriad Genetics (MYGN) and Intermountain Precision Genomics receive the New York State Clinical...
Myriad Genetics (MYGN) Gets Extensive Coverage for BRACAnalysis
Zacks via Yahoo Finance· 2 years agoMyriad Genetics' (MYGN) BRACAnalysis gained expanded coverage from MHLW to identify breast cancer...
Quest Diagnostics (DGX) to Aid Health Equity With New Pact
Zacks via Yahoo Finance· 8 months agoQuest Diagnostics, Inc. DGX recently announced that the company together with Americares, a...
Why Invitae Stock Plummeted by 15% Today
Motley Fool· 2 years agoGenetic medical testing specialist Invitae (NYSE: NVTA) didn't pass the investment test for one researcher late on Thursday. After market hours on...
